Loading organizations...
Key people at Alethea Capital.
Alethea Capital was founded in 2011 by Tony Hsu (Founder/CIO).
Alethea Capital Management, LLC operates as an SEC-registered investment adviser, specializing in public equity and venture capital. The firm employs an unconventional philosophy, building portfolios of uncorrelated assets to generate alpha via domestic, long/short, and global equity strategies. Its venture capital division actively invests in early-stage biotechnology and health technology ventures.
Tony Hsu founded Alethea Capital Management, LLC in March 2011, serving as its principal owner and Chief Investment Officer. His insight, gained from over fifteen years in equity and foreign-currency markets, emphasized contrarian thinking and strategic diversification as crucial for superior investment performance.
Alethea Capital serves sophisticated investors seeking unique growth opportunities across public and private assets. The firm's vision empowers entrepreneurial founders with innovative concepts to positively influence millions, particularly in health technology, while delivering strong returns through its actively managed public market portfolios.
Key people at Alethea Capital.
Alethea Capital was founded in 2011 by Tony Hsu (Founder/CIO).
Alethea Capital has 3 tracked investments across 3 companies. The latest tracked deal is $10.0M Series A in SEngine Precision Medicine in July 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 1, 2022 | SEngine Precision Medicine | $10.0M Series A | WRF Capital | Bangarang Group, Vincere Capital Biotech |
| Nov 19, 2019 | Presidium Health | $3.5M Series A | Alethea Capital | — |
| Nov 13, 2019 | Avidity Biosciences | $100.0M Series C | Roderick Wong | Alexandria Venture Investments, Boxer Capital, Brace Pharma Capital, Cormorant Asset Management, Cureduchenne Ventures, EcoR1 Capital, ELI Lilly And Company, Logos Capital, Partner Fund Management, Perceptive Advisors, ST Pharm, Takeda Ventures |
